Newswise — June 5, 2019 --The American Thoracic Society is concerned by today’s announcement of the Trump Administration’s restrictions on federal support for fetal tissue research.
ATS Research Advocacy Committee Chair Veena Antony, MD, said, “The ATS is very disturbed by the administration’s actions to halt certain NIH scientific research using fetal tissue. Scientific research using fetal tissue is vital for the development of new treatments for many deadly diseases and conditions such as cystic fibrosis and acute lung injury. There are no alternative research models that can replace all fetal tissue research.”
Dr. Antony added, “The ATS urges the Administration to restore federal funding for fetal tissue research across all agencies, including all intramural and extramural research, so that these efforts to develop life-saving treatments and cures can continue.”
Share via Twitter
@atscommunity urges #TrumpAdministration to restore #federal #funding for #fetal tissue #research.
About the American Thoracic Society
Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society’s more than 16,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.
The ATS will hold its 2020 International Conference, May 15-20, in Philadelphia, Pennsylvania, where world-renowned experts will share the latest scientific research and clinical advances in pulmonary, critical care and sleep medicine.